Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis

Mark (Anthony) Sofia, David T. Rubin

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

As biologic-based medication options for ulcerative colitis expand, our understanding of their optimal use in clinical practice is advancing as well. The appropriate use of combination therapy with immunomodulators can reduce the immunogenicity of biologic agents and raise serum drug levels of the biologic. A treat-to-target strategy with objective assessments of disease activity clearly defines the goals of biologic drug treatment. Mucosal healing is an evolving treatment goal and is associated with long-term remission and reduced incidence of colectomy. Furthermore, regular reassessments and therapeutic drug monitoring can allow clinicians to make evidence-based changes in therapy. Biologic drug de-escalation or re-initiation are less well developed topics, but are emerging areas of study. We review the evidence underlying these advances and a modern approach to the use of biologic therapy in ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)548-559
Number of pages12
JournalTherapeutic Advances in Gastroenterology
Volume9
Issue number4
DOIs
StatePublished - Jul 1 2016
Externally publishedYes

Fingerprint

Biological Therapy
Ulcerative Colitis
Pharmaceutical Preparations
Colectomy
Drug Monitoring
Immunologic Factors
Biological Factors
Therapeutics
Biological Products
Incidence
Serum

Keywords

  • biologic therapy
  • infliximab
  • mucosal healing
  • ulcerative colitis
  • vedolizumab

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. / Sofia, Mark (Anthony); Rubin, David T.

In: Therapeutic Advances in Gastroenterology, Vol. 9, No. 4, 01.07.2016, p. 548-559.

Research output: Contribution to journalReview article

@article{76e6401d2e8848eea0cd78c5f59fc564,
title = "Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis",
abstract = "As biologic-based medication options for ulcerative colitis expand, our understanding of their optimal use in clinical practice is advancing as well. The appropriate use of combination therapy with immunomodulators can reduce the immunogenicity of biologic agents and raise serum drug levels of the biologic. A treat-to-target strategy with objective assessments of disease activity clearly defines the goals of biologic drug treatment. Mucosal healing is an evolving treatment goal and is associated with long-term remission and reduced incidence of colectomy. Furthermore, regular reassessments and therapeutic drug monitoring can allow clinicians to make evidence-based changes in therapy. Biologic drug de-escalation or re-initiation are less well developed topics, but are emerging areas of study. We review the evidence underlying these advances and a modern approach to the use of biologic therapy in ulcerative colitis.",
keywords = "biologic therapy, infliximab, mucosal healing, ulcerative colitis, vedolizumab",
author = "Sofia, {Mark (Anthony)} and Rubin, {David T.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1177/1756283X16643242",
language = "English (US)",
volume = "9",
pages = "548--559",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis

AU - Sofia, Mark (Anthony)

AU - Rubin, David T.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - As biologic-based medication options for ulcerative colitis expand, our understanding of their optimal use in clinical practice is advancing as well. The appropriate use of combination therapy with immunomodulators can reduce the immunogenicity of biologic agents and raise serum drug levels of the biologic. A treat-to-target strategy with objective assessments of disease activity clearly defines the goals of biologic drug treatment. Mucosal healing is an evolving treatment goal and is associated with long-term remission and reduced incidence of colectomy. Furthermore, regular reassessments and therapeutic drug monitoring can allow clinicians to make evidence-based changes in therapy. Biologic drug de-escalation or re-initiation are less well developed topics, but are emerging areas of study. We review the evidence underlying these advances and a modern approach to the use of biologic therapy in ulcerative colitis.

AB - As biologic-based medication options for ulcerative colitis expand, our understanding of their optimal use in clinical practice is advancing as well. The appropriate use of combination therapy with immunomodulators can reduce the immunogenicity of biologic agents and raise serum drug levels of the biologic. A treat-to-target strategy with objective assessments of disease activity clearly defines the goals of biologic drug treatment. Mucosal healing is an evolving treatment goal and is associated with long-term remission and reduced incidence of colectomy. Furthermore, regular reassessments and therapeutic drug monitoring can allow clinicians to make evidence-based changes in therapy. Biologic drug de-escalation or re-initiation are less well developed topics, but are emerging areas of study. We review the evidence underlying these advances and a modern approach to the use of biologic therapy in ulcerative colitis.

KW - biologic therapy

KW - infliximab

KW - mucosal healing

KW - ulcerative colitis

KW - vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=84975044549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975044549&partnerID=8YFLogxK

U2 - 10.1177/1756283X16643242

DO - 10.1177/1756283X16643242

M3 - Review article

VL - 9

SP - 548

EP - 559

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 4

ER -